New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

ABSTRACT: Antibodies have proven their high value in antitumor therapy over the last two decades. They are currently being used as the first-choice to treat some of the most frequent metastatic cancers, like HER2⁺ breast cancers or colorectal cancers, currently treated with trastuzumab (Herceptin) and bevacizumab (Avastin), respectively. The impressive therapeutic success of antibodies inhibiting immune checkpoints has extended the use of therapeutic antibodies to previously unanticipated tumor types. These anti-immune checkpoint antibodies allowed the cure of patients devoid of other therapeutic options, through the recovery of the patient's own immune response against the tumor. In this review, we describe how the antibody-based therapies will evolve, including the use of antibodies in

SUBMITTER: Corraliza-Gorjon I 

PROVIDER: S-EPMC5742572 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature